AMGEN INC Annual Report FY2026
AMGEN INC Annual Report FY2026
Quality Scores
Latest Quarterly Earnings Summary
No quarterly summary available yet.
AI Summary
Amgen Inc. remains a powerhouse in the biotechnology sector, transitioning from a legacy biologics provider to a diversified innovator in oncology, inflammation, and rare diseases. Clinical revenue has Grown from $22.99B in 2016 to $36.75B in 2025, supported by the strategic $27.8B acquisition of Horizon Therapeutics. While net income has shown volatility due to tax reforms (2017) and heavy M&A-related amortization, the underlying operating cash flow remains robustly above $9B annually. The company is successfully navigating the patent cliff of legacy assets like Enbrel by ramping up newer…
Key Changes in FY2026
Amgen has undergone a significant transformation from a leader in EPO and Neulasta-driven oncology/hematology to a diversified powerhouse in inflammation, rare diseases, and biosimilars. The decade began with a heavy reliance on legacy blockbusters facing patent cliffs (Enbrel, Neulasta) and transitioned toward higher-growth assets like Repatha and Otezla. The 2019 acquisition of Otezla for $13.4 billion and the 2023 Horizon acquisition represent a pivot toward immunology and rare diseases to mitigate revenue erosion in established products. Geographically, Amgen has expanded its footprint in the Asia-Pacific region, particularly through its strategic collaboration with BeiGene in China. The business is successfully moving up the value chain by focusing on 'first-in-class' biologics and a…
Management Commentary
Management has demonstrated strong execution in pivoting the product pipeline toward high-growth therapeutic areas. Transparency in MD&A regarding the IMPACT of the Inflation Reduction Act on drug pricing suggests a realistic and proactive leadership team. CEO incentives are well-aligned with total shareholder return and pipeline progression, although the high compensation levels are a point of scrutiny. The team successfully integrated several multibillion-dollar targets while maintaining operational focus. Their ability to manage a complex global supply chain for biologics remains a core competency.
Financial Highlights
Revenue growth has accelerated to 3.8% 10-year CAGR, with a notable jump in 2024-2025 as Horizon integration materialized. Gross margins remain high above 75%, though operating margins have faced pressure from R&D intensity and acquisition integration costs. EPS took a major hit in 2017 due to the Tax Cuts and Jobs Act but recovered to a peak of $14.33 in 2025. Stockholders' equity has significantly declined from $29.8B to $8.6B over the decade due to aggressive share repurchases and debt-funded acquisitions. This leverage increases the risk profile but has hyper-charged ROE metrics to over 80% on a compressed equity base.
Major Opportunities
- Consistent cash flow generation exceeding $8B annually
- Strategic acquisition of Horizon Therapeutics diversifying portfolio
- Aggressive pipeline development in high-growth obesity market (MariTide)
Major Risks
- Significant increase in long-term debt levels since 2023
- Noticeable trend of declining operating margins over the last decade
- Heavy reliance on a few blockbuster drugs (Enbrel) facing competition
About This Annual Report
The AMGEN INC FY2026 Annual Report is the company's flagship annual disclosure, filed with SEC EDGAR. It covers the full-year business review, management discussion & analysis (MD&A), audited financial statements, director's report, corporate governance report, auditor's report, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This page consolidates the official PDF and an AI-generated summary so investors can quickly grasp what changed vs. prior years — sales growth, margin trend, cash flow quality, capex, dividends and management outlook — without having to read the entire filing.
Why Use AI?
- Summarises hundreds of pages into a focused executive briefing
- Identifies year-on-year key changes automatically
- Extracts management commentary and tone
- Highlights top risks and opportunities
- Compares business evolution vs. earlier years
- Answers your questions in plain English via Ask AI
Frequently Asked Questions
Related Research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.